GB0905570D0 - Combined vaccines - Google Patents

Combined vaccines

Info

Publication number
GB0905570D0
GB0905570D0 GBGB0905570.8A GB0905570A GB0905570D0 GB 0905570 D0 GB0905570 D0 GB 0905570D0 GB 0905570 A GB0905570 A GB 0905570A GB 0905570 D0 GB0905570 D0 GB 0905570D0
Authority
GB
United Kingdom
Prior art keywords
combined vaccines
vaccines
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0905570.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0905570.8A priority Critical patent/GB0905570D0/en
Publication of GB0905570D0 publication Critical patent/GB0905570D0/en
Priority to JP2011513069A priority patent/JP2011522874A/ja
Priority to AU2009259006A priority patent/AU2009259006A1/en
Priority to KR1020117000394A priority patent/KR20110019417A/ko
Priority to EP09762060A priority patent/EP2303321A1/en
Priority to CA2727322A priority patent/CA2727322A1/en
Priority to US12/997,577 priority patent/US20110200635A1/en
Priority to PCT/IB2009/006038 priority patent/WO2009150532A1/en
Priority to CN2009801230987A priority patent/CN102245203A/zh
Priority to US14/461,852 priority patent/US20140363468A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0905570.8A 2008-06-12 2009-03-31 Combined vaccines Ceased GB0905570D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0905570.8A GB0905570D0 (en) 2009-03-31 2009-03-31 Combined vaccines
CN2009801230987A CN102245203A (zh) 2008-06-12 2009-06-12 用于季节性和大流行保护的联合流感疫苗
EP09762060A EP2303321A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
AU2009259006A AU2009259006A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
KR1020117000394A KR20110019417A (ko) 2008-06-12 2009-06-12 계절 및 유행성 보호를 위한 결합된 인플루엔자 백신
JP2011513069A JP2011522874A (ja) 2008-06-12 2009-06-12 季節性および汎流行性の防御のための混合インフルエンザワクチン
CA2727322A CA2727322A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
US12/997,577 US20110200635A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
PCT/IB2009/006038 WO2009150532A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
US14/461,852 US20140363468A1 (en) 2008-06-12 2014-08-18 Combined influenza vaccines for seasonal and pandemic protection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905570.8A GB0905570D0 (en) 2009-03-31 2009-03-31 Combined vaccines

Publications (1)

Publication Number Publication Date
GB0905570D0 true GB0905570D0 (en) 2009-05-13

Family

ID=40672059

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0905570.8A Ceased GB0905570D0 (en) 2008-06-12 2009-03-31 Combined vaccines

Country Status (9)

Country Link
US (2) US20110200635A1 (enExample)
EP (1) EP2303321A1 (enExample)
JP (1) JP2011522874A (enExample)
KR (1) KR20110019417A (enExample)
CN (1) CN102245203A (enExample)
AU (1) AU2009259006A1 (enExample)
CA (1) CA2727322A1 (enExample)
GB (1) GB0905570D0 (enExample)
WO (1) WO2009150532A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2614802T3 (es) * 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CA2763816A1 (en) * 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
WO2011044152A1 (en) * 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP5884100B2 (ja) * 2011-08-31 2016-03-15 公益財団法人東京都医学総合研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するDIs株由来組換えワクシニアウイルス
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
RU2599496C2 (ru) * 2012-03-06 2016-10-10 Круселл Холланд Б.В. Улучшенная вакцинация против гриппа
JP2016502995A (ja) 2012-12-17 2016-02-01 ユーロシネ ヴァクシンズ アクチエボラーグ 鼻腔内予防接種投薬レジメン
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10588957B2 (en) 2013-10-25 2020-03-17 Leukocare Ag Method for the production of stabile vaccines
WO2016100926A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
JP6719388B2 (ja) * 2014-12-25 2020-07-08 テルモ株式会社 皮内投与インフルエンザワクチン組成物
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN111629751B (zh) * 2018-01-22 2025-02-21 美国政府(由卫生和人类服务部的部长所代表) 广泛保护性灭活流感病毒疫苗
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
TW200700079A (en) * 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition
KR101211386B1 (ko) * 2005-11-04 2012-12-13 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 알루미늄 보조제에 즉석 흡착되는 인플루엔자 백신
US20090304742A1 (en) * 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
WO2007144772A2 (en) * 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
WO2008032219A2 (en) * 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
TWI403518B (zh) * 2007-01-23 2013-08-01 Academia Sinica 一種流感疫苗及其使用方法
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
ES2535101T3 (es) * 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe

Also Published As

Publication number Publication date
WO2009150532A1 (en) 2009-12-17
AU2009259006A1 (en) 2009-12-17
CN102245203A (zh) 2011-11-16
EP2303321A1 (en) 2011-04-06
US20140363468A1 (en) 2014-12-11
US20110200635A1 (en) 2011-08-18
JP2011522874A (ja) 2011-08-04
CA2727322A1 (en) 2009-12-17
KR20110019417A (ko) 2011-02-25

Similar Documents

Publication Publication Date Title
GB0905570D0 (en) Combined vaccines
IL217008A0 (en) Vaccine
ZA201101481B (en) Vaccine
IL208660A0 (en) Coccididosis vaccines
IL208651A0 (en) Vaccine
IL215962A0 (en) Soilid preparation
GB0822001D0 (en) Vaccine
GB201006165D0 (en) Vaccine
GB0810710D0 (en) Vaccine
ZA201007402B (en) Vaccine
GB0816447D0 (en) Vaccine
GB0816284D0 (en) Vaccine
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB201000522D0 (en) Vaccine
GB0801326D0 (en) Vaccines
IL217194A0 (en) Vaccine
GB0909147D0 (en) Vaccines
GB0909146D0 (en) Vaccines
GB0909145D0 (en) Vaccines
GB0909144D0 (en) Vaccines
ZA201107971B (en) Combined measles-malaria vaccine
GB0914545D0 (en) Vaccine
GB0818459D0 (en) Vaccines
GB0907959D0 (en) Easy line-eyeliner

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)